![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TECR |
Gene summary for TECR |
![]() |
Gene information | Species | Human | Gene symbol | TECR | Gene ID | 9524 |
Gene name | trans-2,3-enoyl-CoA reductase | |
Gene Alias | GPSN2 | |
Cytomap | 19p13.12 | |
Gene Type | protein-coding | GO ID | GO:0000038 | UniProtAcc | B3KSQ1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9524 | TECR | P48T-E | Human | Esophagus | ESCC | 5.98e-76 | 1.38e+00 | 0.0959 |
9524 | TECR | P49T-E | Human | Esophagus | ESCC | 3.05e-22 | 2.52e+00 | 0.1768 |
9524 | TECR | P52T-E | Human | Esophagus | ESCC | 2.30e-100 | 2.30e+00 | 0.1555 |
9524 | TECR | P54T-E | Human | Esophagus | ESCC | 6.59e-82 | 2.32e+00 | 0.0975 |
9524 | TECR | P56T-E | Human | Esophagus | ESCC | 1.53e-11 | 2.04e+00 | 0.1613 |
9524 | TECR | P57T-E | Human | Esophagus | ESCC | 1.34e-85 | 1.58e+00 | 0.0926 |
9524 | TECR | P61T-E | Human | Esophagus | ESCC | 8.86e-52 | 1.60e+00 | 0.099 |
9524 | TECR | P62T-E | Human | Esophagus | ESCC | 4.72e-111 | 2.27e+00 | 0.1302 |
9524 | TECR | P65T-E | Human | Esophagus | ESCC | 5.44e-73 | 1.75e+00 | 0.0978 |
9524 | TECR | P74T-E | Human | Esophagus | ESCC | 2.77e-71 | 2.28e+00 | 0.1479 |
9524 | TECR | P75T-E | Human | Esophagus | ESCC | 1.18e-95 | 1.95e+00 | 0.1125 |
9524 | TECR | P76T-E | Human | Esophagus | ESCC | 1.01e-84 | 1.75e+00 | 0.1207 |
9524 | TECR | P79T-E | Human | Esophagus | ESCC | 1.15e-83 | 1.61e+00 | 0.1154 |
9524 | TECR | P80T-E | Human | Esophagus | ESCC | 2.32e-70 | 2.60e+00 | 0.155 |
9524 | TECR | P82T-E | Human | Esophagus | ESCC | 6.05e-34 | 2.06e+00 | 0.1072 |
9524 | TECR | P83T-E | Human | Esophagus | ESCC | 3.54e-80 | 3.09e+00 | 0.1738 |
9524 | TECR | P84T-E | Human | Esophagus | ESCC | 1.24e-28 | 2.34e+00 | 0.0933 |
9524 | TECR | P89T-E | Human | Esophagus | ESCC | 6.14e-36 | 2.89e+00 | 0.1752 |
9524 | TECR | P91T-E | Human | Esophagus | ESCC | 2.89e-28 | 3.68e+00 | 0.1828 |
9524 | TECR | P94T-E | Human | Esophagus | ESCC | 4.90e-07 | 1.90e+00 | 0.0879 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000915214 | Breast | IDC | purine ribonucleotide biosynthetic process | 34/1434 | 169/18723 | 1.63e-07 | 8.92e-06 | 34 |
GO:004639013 | Breast | IDC | ribose phosphate biosynthetic process | 36/1434 | 190/18723 | 3.40e-07 | 1.73e-05 | 36 |
GO:000926013 | Breast | IDC | ribonucleotide biosynthetic process | 35/1434 | 182/18723 | 3.40e-07 | 1.73e-05 | 35 |
GO:000915014 | Breast | IDC | purine ribonucleotide metabolic process | 55/1434 | 368/18723 | 1.30e-06 | 5.72e-05 | 55 |
GO:001969314 | Breast | IDC | ribose phosphate metabolic process | 58/1434 | 396/18723 | 1.31e-06 | 5.73e-05 | 58 |
GO:000675313 | Breast | IDC | nucleoside phosphate metabolic process | 68/1434 | 497/18723 | 2.01e-06 | 8.23e-05 | 68 |
GO:000911713 | Breast | IDC | nucleotide metabolic process | 67/1434 | 489/18723 | 2.28e-06 | 9.05e-05 | 67 |
GO:000925914 | Breast | IDC | ribonucleotide metabolic process | 56/1434 | 385/18723 | 2.47e-06 | 9.63e-05 | 56 |
GO:000616413 | Breast | IDC | purine nucleotide biosynthetic process | 34/1434 | 191/18723 | 3.11e-06 | 1.15e-04 | 34 |
GO:190129313 | Breast | IDC | nucleoside phosphate biosynthetic process | 41/1434 | 256/18723 | 5.15e-06 | 1.73e-04 | 41 |
GO:000616314 | Breast | IDC | purine nucleotide metabolic process | 56/1434 | 396/18723 | 5.90e-06 | 1.90e-04 | 56 |
GO:007252213 | Breast | IDC | purine-containing compound biosynthetic process | 34/1434 | 200/18723 | 8.79e-06 | 2.50e-04 | 34 |
GO:000916513 | Breast | IDC | nucleotide biosynthetic process | 40/1434 | 254/18723 | 1.01e-05 | 2.81e-04 | 40 |
GO:007252114 | Breast | IDC | purine-containing compound metabolic process | 57/1434 | 416/18723 | 1.28e-05 | 3.31e-04 | 57 |
GO:007233012 | Breast | IDC | monocarboxylic acid biosynthetic process | 29/1434 | 214/18723 | 1.91e-03 | 1.83e-02 | 29 |
GO:001605313 | Breast | IDC | organic acid biosynthetic process | 39/1434 | 316/18723 | 2.13e-03 | 1.99e-02 | 39 |
GO:000663312 | Breast | IDC | fatty acid biosynthetic process | 23/1434 | 163/18723 | 3.21e-03 | 2.70e-02 | 23 |
GO:004639413 | Breast | IDC | carboxylic acid biosynthetic process | 38/1434 | 314/18723 | 3.39e-03 | 2.83e-02 | 38 |
GO:000915223 | Breast | DCIS | purine ribonucleotide biosynthetic process | 34/1390 | 169/18723 | 7.77e-08 | 4.47e-06 | 34 |
GO:004639022 | Breast | DCIS | ribose phosphate biosynthetic process | 36/1390 | 190/18723 | 1.59e-07 | 8.19e-06 | 36 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00062 | Colorectum | SER | Fatty acid elongation | 11/1580 | 27/8465 | 6.38e-03 | 3.68e-02 | 2.67e-02 | 11 |
hsa000621 | Colorectum | SER | Fatty acid elongation | 11/1580 | 27/8465 | 6.38e-03 | 3.68e-02 | 2.67e-02 | 11 |
hsa012129 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa0121214 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa012122 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
hsa01040 | Liver | Cirrhotic | Biosynthesis of unsaturated fatty acids | 14/2530 | 27/8465 | 1.36e-02 | 4.25e-02 | 2.62e-02 | 14 |
hsa012123 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
hsa010401 | Liver | Cirrhotic | Biosynthesis of unsaturated fatty acids | 14/2530 | 27/8465 | 1.36e-02 | 4.25e-02 | 2.62e-02 | 14 |
hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
hsa000622 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
hsa010402 | Liver | HCC | Biosynthesis of unsaturated fatty acids | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
hsa012125 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
hsa0006211 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
hsa010403 | Liver | HCC | Biosynthesis of unsaturated fatty acids | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
hsa012128 | Oral cavity | OSCC | Fatty acid metabolism | 35/3704 | 57/8465 | 5.37e-03 | 1.29e-02 | 6.55e-03 | 35 |
hsa0121213 | Oral cavity | OSCC | Fatty acid metabolism | 35/3704 | 57/8465 | 5.37e-03 | 1.29e-02 | 6.55e-03 | 35 |
hsa012127 | Prostate | BPH | Fatty acid metabolism | 19/1718 | 57/8465 | 1.44e-02 | 4.17e-02 | 2.58e-02 | 19 |
hsa0121212 | Prostate | BPH | Fatty acid metabolism | 19/1718 | 57/8465 | 1.44e-02 | 4.17e-02 | 2.58e-02 | 19 |
hsa0121221 | Prostate | Tumor | Fatty acid metabolism | 23/1791 | 57/8465 | 7.60e-04 | 3.59e-03 | 2.23e-03 | 23 |
hsa010404 | Prostate | Tumor | Biosynthesis of unsaturated fatty acids | 12/1791 | 27/8465 | 5.53e-03 | 1.93e-02 | 1.19e-02 | 12 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TECR | SNV | Missense_Mutation | rs763449006 | c.79N>A | p.Ala27Thr | p.A27T | Q9NZ01 | protein_coding | tolerated(0.54) | benign(0.015) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TECR | SNV | Missense_Mutation | novel | c.252N>T | p.Gln84His | p.Q84H | Q9NZ01 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TECR | SNV | Missense_Mutation | novel | c.292N>T | p.Pro98Ser | p.P98S | Q9NZ01 | protein_coding | deleterious(0.01) | benign(0.266) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TECR | SNV | Missense_Mutation | rs765698953 | c.514N>A | p.Ala172Thr | p.A172T | Q9NZ01 | protein_coding | tolerated(0.26) | benign(0.141) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TECR | SNV | Missense_Mutation | c.118N>A | p.His40Asn | p.H40N | Q9NZ01 | protein_coding | tolerated(0.31) | benign(0) | TCGA-FU-A23K-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
TECR | SNV | Missense_Mutation | novel | c.812C>A | p.Ser271Tyr | p.S271Y | Q9NZ01 | protein_coding | deleterious(0) | possibly_damaging(0.567) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
TECR | SNV | Missense_Mutation | rs545666123 | c.266C>T | p.Thr89Met | p.T89M | Q9NZ01 | protein_coding | tolerated(0.11) | benign(0.029) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
TECR | SNV | Missense_Mutation | c.422N>A | p.Arg141His | p.R141H | Q9NZ01 | protein_coding | deleterious(0.02) | benign(0.006) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
TECR | SNV | Missense_Mutation | rs763449006 | c.79N>A | p.Ala27Thr | p.A27T | Q9NZ01 | protein_coding | tolerated(0.54) | benign(0.015) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TECR | SNV | Missense_Mutation | novel | c.899N>A | p.Arg300His | p.R300H | Q9NZ01 | protein_coding | deleterious(0.03) | benign(0.212) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |